PuraVida62 schreef op 5 mei 2021 15:31:
'Ik zie geen succesvolle overname komen'. zegt hier iemand.
Toch leuk om dan eens hierover na te denken:
After $600M sales hit from pandemic, Merck's open to 'all forms' of M&A deals, incoming CEO says.“We are open to any opportunity to add a meaningful asset,” president and soon-to-be CEO Rob Davis said on a Thursday call with investors. “We are open to all forms of deals and we have the capital” for those deals, he added.
It'll soon have some extra cash on hand, too, thanks to the spinoff of Organon, which is expected to wrap up on June 2. Once the spinoff closes, Merck expects "to receive a special tax-free dividend of $9 billion, which we hope to deploy in a value-enhancing strategic business development opportunity," chief financial officer Caroline Litchfield said'.www.fiercepharma.com/pharma/merck-say...-Waar zit nu een vestiging Organon? Oss ja, Pivotpark!
-Wie is afkomstig van Merck? Barbara Yanni!
Barbara retired from Merck & Co., Inc. in 2014 after 12 years as Merck’s Vice President and Chief Licensing Officer.
'Barbara and her licensing team at
Merck successfully structured and negotiated agreements to acquire rights to over 150 compounds, programs and technologies to enhance Merck’s pipeline. Barbara greatly increased Merck’s visibility as a preferred partner – Merck was named “best biopharma partner” in an independent survey by Boston Consulting Group. Barbara maintains extensive contacts throughout the industry'.
www.bioexecinstitute.com/yanni/-Wat heeft Sijmen de Vries meerdere malen gezegd: 'Elke kleine biotech wordt op een bepaald moment door een grote Farmaceut overgenomen'.
Het is hier al eerder gezegd: Pharming is bij slagen van de clinical trials (vooral AKI en PE straks, samen met de trial 'cytokinestorm') en haar licentie Leniolisib de ideale kandidaat om overgenomen te worden. Met de spinoff van Organon kan Merck straks gemakkelijk eens naar Pharming kijken....stay tuned!